<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00479986</url>
  </required_header>
  <id_info>
    <org_study_id>ATS-K-016</org_study_id>
    <nct_id>NCT00479986</nct_id>
  </id_info>
  <brief_title>Effects of Pioglitazone in Type 2 Diabetes Mellitus and Coronary Heart Disease</brief_title>
  <acronym>PIOcard</acronym>
  <official_title>Effects of Pioglitazone in Patients With Type 2 Diabetes Mellitus and Coronary Heart Disease at High Risk for Vascular Complications : A Placebo-Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IKFE Institute for Clinical Research and Development</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johannes Gutenberg University Mainz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IKFE Institute for Clinical Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the study is to investigate the impact of a 4 week treatment with pioglitazone
      (in comparison to placebo) on biomarkers for atherosclerosis and cardiovascular risk, as well
      as the degree of activation of the immune system, when given on top of an anti-diabetic
      treatment (metformin and/or sulfonylurea drugs) that has already resulted in good glycemic
      control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PPARgamma activation by pioglitazone has shown to be associated with an improvement of
      cardiovascular risk when measured with clinical (assessement of intima-media-thickness) or
      biochemical (hsCRP, MMP-9 etc.) markers. Well controlled patients (HbA1c &lt; 8.0 %) will
      receive either pioglitazone or placebo (randomised, double-blind) for 4 weeks. Blood will be
      drawn to investigate the change in cardiovascular or metabolic markers and mRNA will be
      isolated from circulating mononuclear cells to investiagte the degree of activation of the
      immune system, which is another measure for the risk of atherosclerosis development.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Short-term effect of Pioglitazone on Markers of vascular risk (MMP-9, hsCRP, monocyte activation)</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic control (HbA1c, Glucose)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Pioglitazone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pioglitazone</intervention_name>
    <arm_group_label>Pioglitazone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 2 diabetes mellitus

          -  stable oral treatment with metfromin and/or sulfonylurea

          -  age 20 - 80 years

          -  angiographically confirmed atherosclerosis or hsCRP &gt; 1 mg/l

        Exclusion Criteria:

          -  type 1 diabetes

          -  HbA1c &gt; 8.5 %

          -  severe disease

          -  acute coronary syndrome

          -  contraindications to pioglitazone (heart failure etc.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Forst, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IKFE - Institute for Clinical Research and Development, Mainz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andreas Pf√ºtzner, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>IKFE - Institute for Clinical Research and Development, Mainz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr. Michael Morcos</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IKFE</name>
      <address>
        <city>Mainz</city>
        <zip>55116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2007</study_first_submitted>
  <study_first_submitted_qc>May 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2007</study_first_posted>
  <last_update_submitted>March 31, 2015</last_update_submitted>
  <last_update_submitted_qc>March 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2015</last_update_posted>
  <keyword>diabetes mellitus</keyword>
  <keyword>monocyte activation</keyword>
  <keyword>cardiovascular risk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

